The impact of ageing on the barriers to drug delivery

Journal of Controlled Release

Volumn 161, Issue 2, 2012, Pages 389-398

  Perrie, Yvonne ^a   Badhan, Raj K Singh ^a   Kirby, Daniel J ^a   Lowry, Deborah ^a   Mohammed, Afzal R ^a   Ouyang, Defang ^a  

^a ASTON UNIVERSITY   (United Kingdom)

Author keywords

Ageing; Drug delivery; Ocular route; Oral route; Pulmonary route; Topical delivery

Indexed keywords

AGEING; OCULAR ROUTE; ORAL ROUTE; PULMONARY ROUTE; TOPICAL DELIVERY;

BIOCHEMISTRY; BIOLOGICAL ORGANS; TISSUE;

DRUG DELIVERY;

AZITHROMYCIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CARDIAC GLYCOSIDE; CHLORAMPHENICOL; CLOROCIL; CYCLOSPORIN; DEXAMETHASONE; DEXAMETHASONE PLUS TOBRAMYCIN; DICLOFENAC; DIURETIC AGENT; ESTRADIOL; ESTROGEN; EYE DROPS; FLUOCINOLONE ACETONIDE; GANCICLOVIR; HYDROXYPROPYLCELLULOSE; INDOMETACIN; LODOXAMIDE; LODOXAMIDE TROMETAMOL; PEGAPTANIB; PILOCARPINE; POLYMER; RANIBIZUMAB; RESTASI; RYSMON; TESTOSTERONE; TIMOLOL; UNCLASSIFIED DRUG;

AGING; ALLERGIC CONJUNCTIVITIS; BACTERIAL CONJUNCTIVITIS; BLEPHARITIS; CONJUNCTIVITIS; CYTOMEGALOVIRUS RETINITIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG SOLUBILITY; DRY EYE; EYE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GLAUCOMA; HORMONE SUBSTITUTION; HUMAN; HYDROGEL; LUNG; LUNG CAPACITY; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA EDEMA; REVIEW; STOMACH; STOMACH EMPTYING; SUSPENSION; TRANSDERMAL DRUG ADMINISTRATION; UVEITIS;

AGING; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; HUMANS; PHARMACOKINETICS;

EID: 84862691464     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.01.020     Document Type: Review

References (123)

1. R. Noble, Drug therapy in the elderly, Metabolism 52 (10) (2003) 27-30.
2. J.H. Baron, Studies of basal and peak acid output with an augmented histamine test, Gut 4 (1963) 136-144.
3. M. Kekki, I.M. Samloff, T. Ihamaki, K. Varis, M. Siurala, Age- and sex-related behaviour of gastric acid secretion at the population level, Scand. J. Gastroenterol. 17 (1982) 737-743.
4. M.A. Evans, E.J. Triggs, M. Cheung, G.A. Broe, H. Creasey, Gastric emptying rate in the elderly: implications for drug therapy, J. Am. Geriatr. Soc. 29 (1981) 201-205.
5. A. Bender, The effect of increasing age on the distribution of peripheral blood flow in man, J. Am. Geriatr. Soc. 16 (1965) 192-198.
6. P.M. Warren, M.A. Pepperman, R.D. Montgomery, Age changes in small-intestinal mucosa, Lancet 2 (1978) 849-850.
7. P.B. Watkins, The barrier function of CYP3A4 and P-glycoprotein in the small bowel, Adv. Drug Deliv. Rev. 27 (1997) 161-170.
8. V.J. Wacher, C.Y. Wu, L.Z. Benet, Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy, Mol. Carcinog. 1995 (13) (1995) 129-134.
9. A. Anantharaju, A. Feller, A. Chedid, Aging liver, Rev. Gerontol. 48 (2002) 343-353.
10. D.J. Greenblatt, M.K. Divoll, J.S. Harmatz, R.I. Shader, Antipyrine absorption and disposition in the elderly, Pharmacology 36 (1988) 125-133.
11. C.M. Castleden, C.M. Kaye, R.L. Parsons, The effect of age on plasma levels of propranolol and practolol in man, Br. J. Clin. Pharmacol. 2 (1975) 303-306.
12. M. Divoll, B. Ameer, D.R. Abernethy, D.J. Greenblatt, Age does not alter acetaminophen absorption, J. Am. Geriatr. Soc. 30 (1982) 240-244.
13. S. Dawling, P. Crome, Clinical pharmacokinetic considerations in the elderly. An update, Clin. Pharmacokinet. 17 (1989) 236-263.
14. K. Turnheim, Drug dosage in the elderly. Is it rational? Drugs Aging 13 (1998) 357-379.
15. R.E. Vestal, Aging and pharmacology, Cancer 80 (1997) 1302-1310.
16. E.W. Campion, L.O. deLabry, R.J. Glynn, The effect of age on serum albumin in healthy males: report from the Normative Aging Study, J. Gerontol. 43 (1988) 18-20.
17. D.J. Greenblatt, E.M. Sellers, J. Koch-Weser, Importance of protein binding for the interpretation of serum or plasma drug concentrations, J. Clin. Pharmacol. 22 (1982) 259-263.
18. W.J. MacLennan, P. Martin, B.J. Mason, Protein intake and serum albumin levels in the elderly, Gerontology 23 (1977) 360-367.
19. D.J. Greenblatt, Reduced serum albumin concentration in the elderly: report from the Boston. Collaborative Drug Surveillance Program, J. Am. Geriatr. Soc. 27 (1979) 20-22.
20. S.M. Wallace, R.K. Verbeeck, Plasma protein binding of drugs in the elderly, Clin. Pharmacokinet. 12 (1987) 41-72.
21. M.J. Hayes, M.J. Langman, A.H. Short, Changes in drug metabolism with increasing age: 1. Warfarin binding and plasma proteins, Br. J. Clin. Pharmacol. 2 (1975) 69-72.
22. D.L. Schmucker, Aging and drug disposition: an update, Pharmacol. Rev. 37 (1985) 133-148.
23. D.G. Le Couteur, A.J. McLean, The aging liver. Drug clearance and an oxygen diffusion barrier hypothesis, Clin. Pharmacokinet. 34 (1998) 359-373.
24. K. O'Malley, J. Crooks, E. Duke, I.H. Stevenson, Effect of age and sex on human drug metabolism, Br. Med. J. 3 (1971) 607-609.
25. C.G. Swift, M. Homeida, M. Halliwell, C.J. Roberts, Eur. J. Clin. Pharmacol. 14 (1978) 149-152.
26. P. Maurel, The CYP3A family, in: C. Ioannides (Ed.), Cytochromes P450: Metabolic and Toxicological Aspects, CRC Press. Inc, Boca Raton, FL, 1996, pp. 241-270.
27. T.N. Johnson, S.T. Tanner ST, C.J. Taylor, G.T. Tucker, Antipyrine disposition and liver size in the elderly, Br. J. Clin. Pharmacol. 51 (2001) 415-460.
28. V.A. Portnoi, Digitalis delirium in elderly patients, J. Clin. Pharmacol. 19 (1979) 747-750.
29. R. Oberbauer, P. Krivanen, K. Turnheim, Pharmacokinetics of indomethacin in the elderly, Clin. Pharmacokinet. 24 (1993) 428-434.
30. A.E. Ritch, W.N. Perera, C.J. Jones, Pharmacokinetics of azapropazone in the elderly, Br. J. Clin. Pharmacol. 14 (1982) 116-119.
31. D.S. Hewick, P. Newbury, S. Hopwood, G. Naylor, J. Moody, Pharmacokinetics of azapropazone in the elderly, Br. J. Clin. Pharmacol. 4 (1997) 201-205.
32. S. Stegemann, F. Ecker, M. Maio, P. Kraahs, R. Wohlfart, J. Breitkreutz, A. Zimmer, D. Bar-shalom, R. Hettrich, B. Broegmann, Geriatric drug therapy: neglecting the inevitable majority, Ageing Res. Rev. 9 (2010) 384-398.
33. I.J. Cook, P.J. Kahrilas, AGA technical review on management of oropharyngeal dysphagia, Gastroenterology 116 (1999) 455-478.
34. S. Turner, A.J. Nunn, K. Fielding, I. Choonara, Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study, Acta Paediatr. 88 (1999) 965-968.
35. T.J. Cook, S. Edwards, C. Gyemah, M. Shah, I. Shah, T. Fox, Variability in tablet fragment weights when splitting unscored cyclobenzaprine 10 mg tablets, J. Am. Pharm. Assoc. 44 (2003) 584-586.
36. D.J. Kirby, U. Shah, M. Orlu-Gul, C. Tuleu, A.J. Nunn, J.F. Marriott, Time to strengthen the evidence base for paediatric formulations, Clin. Pharm. 3 (2011) 28-29 3.
37. P.C. Kayumba, N. Huyghebaert, C. Cordella, J.D. Ntawukuliryayo, C. Vervaet, J.P. Remon, Quinine sulphate pellets for flexible pediatric drug dosing: formulation development and evaluation of taste-masking efficiency using the electronic tongue, Eur. J. Pharm. Biopharm. 66 (2007) 460-465.
38. Y. Gao, F.D. Cui, Y. Guan, L. Yang, Y.S. Wang, L.N. Shang, Preparation of roxithromycin-polymeric microspheres by the emulsion solvent diffusion method for taste masking, Int. J. Pharm. 318 (2006) 62-69.
39. K. Shini, Y. Iwao, A. Miyagishma, S. Itai, Optimization of a novel wax matrix system using aminoalkyl methacrylate copolymer E and ethylcellulose to suppress the bitter taste of acetaminophen, Int. J. Pharm. 395 (2010) 71-77.
40. H.J. Robson, D.Q. Craig, D. Deutsch, An investigation into the release of cefuroxime axetil from taste-masked stearic acid microspheres. Part 1: the influence of the dissolution medium on the drug release profile and the physical integrity of the microspheres, Int. J. Pharm. 190 (1999) 183-192.
41. H.J. Robson, D.Q. Craig, D. Deutsch, An investigation into the release of cefuroxime axetil from taste-masked stearic acid microspheres. II. The effects of buffer composition on drug release, Int. J. Pharm. 195 (2000) 137-145.
42. L. Oddo, G. Masci, C. Di eo, D. Capitani, L. Mannina, R. Lamanna, S. De Santis, F. AlHaique, T. Coviello, P. Matricardi, Novel thermosensitive calcium alginate microspheres: physico-chemical characterization and delivery properties, Acta Biomater. 6 (2010) 3657-3664.
43. S.S. Davis, Formulation strategies for absorption windows, Drug Discov. Today 10 (2005) 4249-4257.
44. H.A. Bardelmeijer, O. Van Tellingen, J.H. Schellens, J.H. Beignen, The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery, Invest. New Drugs 18 (2000) 231-241.
45. S.S. Davis, J.G. Hardy, J.W. Fara, Transit of pharmaceutical dosage forms through the small intestine, Gut 27 (1986) 886-892.
46. N. Washington, C. Washington, C. Wilson, Physiological Pharmaceutics, Barriers to Drug Absorption, 2nd edn, Taylor and Francis, 2001.
47. N. Rouge, P. Buri, E. Doelker, Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery, Int. J. Pharm. 136 (1996) 117-139.
48. B.N. Singh, K.H. Kim, Floating drug delivery systems: an approach to oral controlled drug delivery via gastric retention, J. Control. Release 63 (2000) 235-259.
49. K.D. Kroening, N.P. Simmerman, P. Bass, J.A. Oaks, Guanosine 3′,5′-cyclic monophosphate: a tapeworm-secreted signal molecule communicating with the rat host's small intestine, J. Parasitol. 89 (2003) 1136-1141.
50. A.J. Caston, S.S. Davis, P. Williams, The potential of fimbrial proteins for delaying intestinal transit of oral drug delivery systems, Proc. Intern Symp. Control Rel. Bioact. Mater 17 (1990) 313-314.
51. M.J. Montisci, A. Dembri, G. Giovannuci, H. Chacun, D. Duchene, G. Ponchel, Gastrointestinal transit and mucoadhesion of colloidal suspensions of Lycopersicon esculentum L. and Lotus tetragonolobus lectin-PLA microsphere conjugates in rats, Pharm. Res. 18 (2001) 829-837.
52. A. Morabia, M.C. Costanza, International variability in ages at menarche, first livebirth, and menopause. World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives, Am. J. Epidemiol. 148 (1998) 1195-1205.
53. P. Dandona, M.T. Rosenberg, A practical guide to male hypogonadism in the primary care setting, Int. J. Clin. Pract. 64 (2010) 682-696.
54. L.J. Gooren, Advances in testosterone replacement therapy, Front. Horm. Res. 37 (2009) 32-51.
55. A. Naik, Y.N. Kalia, R.H. Guy, Transdermal drug delivery: overcoming the skin's barrier function, Pharm Sci Technol To 3 (2000) 318-326.
56. V.W. Nitti, S. Sanders, D.R. Staskin, Transdermal delivery of drugs for urologic applications: basic principles and applications, Urology 67 (2006) 657-664.
57. J. Kielhorn, S. Melching-Kollmuss, Dermal Adsorption, World Health Organization, Geneva, 2006.
58. C. Ramachandran, D. Fleisher, Transdermal delivery of drugs for the treatment of bone diseases, Adv. Drug Deliv. Rev. 42 (2000) 197-223.
59. R.J. Scheuplein, I.H. Blank, Permeability of the skin, Physiol. Rev. 41 (1971) 702-747.
60. S. Singh, Skin structure and function, in: J. Kielhorn, S. Melching-Kollmuss (Eds.), Dermal Adsorption, World Health Organization, Geneva, 2006.
61. I. Ale, J. Lachapelle, H.I. Maibach, Skin tolerability associated with transdermal drug delivery systems: an overview, Adv. Ther. 26 (2009) 920-935.
62. C. Levin, H.I. Maibach, Transdermal drug delivery system: an overview, in: H. Zhai, K.P. Wilhelm, H.I. Mai-Bach (Eds.), Marzulli and Maibach's Dermato-Toxicology, 7th edition, CRC Press, Boca Raton, FL, 2008, pp. 101-106.
63. L.Z. Kaestli, A.F. Wasilewski-Rasca, P. Bonnabry, F. Vogt-Ferrier, Use of transdermal drug formulations in the elderly, Drug Aging 2594 (2008) 269-280.
64. M.S. Dunnill, Postnatal growth of the lung, Thorax 17 (1962) 329.
65. J.C. Hogg, J. Williams, J.B. Richardson, P.T. Macklem, W.M. Thurlbeck, Age as a factor in the distribution of lower-airway conductance and in the pathologic anatomy of obstructive lung disease, N. Engl. J. Med. 28 (2) (1970) 1283.
66. L.C. Stigol, G.F. Vawter, J. Mead, Studies on elastic recoil of the lung in a pediatric population, Am. Rev. Respir. Dis. 10 (5) (1972) 552.
67. W.M. Thurlbeck, Internal surface area and other measurements in emphysema, Thorax 2 (2) (1967) 483.
68. R.H. Ingram, C.P. O'Cain, Frequent dependence of compliance in apparently healthy smokers versus non-smokers, Physio-Pathol. Respir. 7 (1971) 195.
69. J.A. Pierce, R.V. Ebert, Biochemistry of aging in the lung, in aging of the lung, Thorax 2 (1965) 469.
70. R. John, J. Thomas, Chemical composition of elastins isolated from aortas and pulmonary tissues of humans of different ages, Biochem. J. 12 (7) (1972) 261.
71. T. Sugihara, C.J. Martin, J. Hildebrandt, Length-tension properties of alveolar wall in man, J. Appl. Physiol. 3 (1971) 874.
72. W.F. McDonnell, P.L. Enright, D.E. Abbey, S.F. Knutsen, J.A. Peters, R.J. Burchette, M.D. Lebowitz, Spirometric reference equations for older adults, Respir. Med. 92 (1998) 914-921.
73. K.J. Welch, T.D. Kinney, The effect of patent ductus arteriousus and of interauricular and interventricular septal defects on the development of pulmonary vascular lesions, Am. J. Pathol. 2 (9) (1948) 727.
74. M. Semmens, The pulmonary artery in the normal aged lung, Br. J. Dis. Chest 6 (4) (1970) 65.
75. V. Tapio, H. Asta, L.-A. Paivi, P. Paivi, Relation between atherosclerotic calcifications detected in chest computed tomography and lung function, Arch. Bronconeumol. (English Edition) 45 (8) (2009) 376-381.
76. E.D. Chan, C.H. Welsh, Geriatric respiratory medicine, Chest 114 (1998) 1704-1733.
77. A.H. Boer (a), H.M.I. de, Winter, C.F. Lerk, Int. J. Pharm. 130 (2) (1996) 231-244.
78. A.H. Boer, G.K. Bolhuis, D. Gjaltema, P. Hagedoorn, Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers: Part 3: the effect of flow increase rate (FIR) on the in vitro drug release from the Pulmicort 200 Turbuhaler, Int. J. Pharm. 153 (1) (1997) 67-77.
79. A.H. Boer, D. Gjaltema, P. Hagedoorn, Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers Part 2: effect of peak flow rate (PIFR) and inspiration time on the in vitro drug release from three different types of commercial dry powder inhalers, Int. J. Pharm. 138 (1) (1996) 45-56.
80. H. Ohtsuka, K. Soma, T. Takahashi, T. Tomita, Kokyu TO Junkan Pulmonary gas exchange function of supine elderly subjects in relation to closing volumes, Respir. Circ. 24 (1976) 329-333.
81. K.C. Meyer, Lung infections and aging, Ageing Res. Rev. 3 (1) (2004) 55-67.
82. A. Litonjua, R. Lazarus, D. Sparrow, D. DeMolles, S.T. Weiss, Lung function in type 2 diabetes: the Normative Aging Study, Respir. Med. 99 (12) (2005) 1583-1590.
83. W.F. McDonnell, E. Seal, Relationships between lung function and physical characteristics in young adult black and white males and females, Eur. Respir. 4 (1991) 279-289.
84. E.M. Richard, H. Genevieve, H.K. Wahlen, O. Lars, L. Wen, Protection of the lungs from acid during aspiration, Am. J. Med. 1 (3) (2001) 56-59
85. Volume 111, Issue 8, Supplement.
86. J.S. Patton, Mechanisms of macromolecule absorption by the lungs, advanced drug delivery reviews, Pulm. Polypeptide Polynucleic Acid Deliv. 19 (1) (1996) 3-36.
87. B.F. Sean, A. Talissa, S.R. Altes, S.R. Panth, M.D. Evans, B. Waters, J.P. Mugler III, F.R. Korosec, T.M. Grist, M. Silverman, M. Salerno, J. Owers-Bradley, Detection of age-dependent changes in healthy adult lungs with diffusion-weighted 3He MRI, Acad. Radiol. 12 (11) (2005) 1385-1393.
88. M.E. Starr, J. Uedai, S.B. Yamamoto, M. Evers, H. Saito, The effects of aging on pulmonary oxidative damage, protein nitration, and extracellular superoxide dismutase down-regulation during systemic inflammation, Free Radic. Biol. Med. 50 (2) (2011) 371-380.
89. C. Schleh, B. Rothen-Rutishauser, W.G. Kreyling Wueo, J. Pharm. Biopharm. 77 (2011) 350-252.
90. P. Eggleton, K.M.B. Reid, The influence of pulmonary surfactant on nanoparticle drug delivery systems, Curr. Opin. Immunol. 11 (1) (1999) 28-33.
91. Y. Sibille, H.Y. Reynolds, Macrophages and polymorphonnuclear neutophils in lung defense and injury, Am. Rev. Respir. Dis. 141 (1990) 471-501.
92. S. Welch, M. Eckstein, The ageing eye - threats to vision and their treatments, CME J. Geriatr. Med. 10 (2) (2008) 58-61.
93. J. Barar, A.R. Javadzadeh, Y. Omidi, Ocular novel drug delivery: impacts of membranes and barriers, Expert Opin. Drug Deliv. 5 (5) (2008) 567-581.
94. R. Gaudana, J. Jwala, S.H.S. Boddu, A.K. Mitra, Recent perspectives in ocular drug delivery, Pharm. Res. 26 (2009) 1197-1216.
95. N. Bodor, P. Buchwald, AAPS J. 7 (2005) E820-E833.
96. W.D. Mather, J.A. Lane, M.B. Zimmerman, Cont. Lens Anterior Eye 4 (2010) 171-175.
97. C. Maissa, M. Guillon, Cont Les Anterior eye 4 (2010) 176-182.
98. T. Loftssona, T. Jarvinen, Cyclodextrins in ophthalmic drug delivery, Adv. Drug Deliv. Rev. 36 (1999) 59-79.
99. B.K. Nanjawade, F.V. Manvi, A.s Manjappa, In situ-forming hydrogels for sustained ophthalmic drug delivery, J. Control. Release 122 (2007) 119-134.
100. Cyclosporin - allergan. Ciclosporin - allergan, cyclosporin opthalmic emulsion, cyclosporine = Allergan, Restatis. Drugs R D. 4 (2) (2003) 126-127. PMID:12718570.
101. M.F. Saettone, L. Salminen, Ocular inserts for topical delivery, Adv. Drug Deliv. Rev. 16 (1995) 95-106.
102. J.B. Ciolino, C.H. Dohlman, D.S. Kohane, Contact lenses for drug delivery, Semin. Ophthalmol. 24 (2009) 156-160.
103. E. Eljarrat-Binstock, J. Pe'er, A.J. Domb, New techniques for drug delivery to the posterior eye segment, Pharm. Res. 27 (2010) 530-543.
104. S.S. Lee, M.R. Robinson, Drug delivery systems for retinal diseases. A review, Ophthalmic Res. 41 (2009) 124-135.
105. Y.E. Choonara, V. Pillay, M.P. Danckwerts, T.R. Carmichael, L.C. Du Toit, A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases, J. Pharm. Sci. 99 (2010) 2219-2239.
106. J.L. Bourges, C. Bloquel, A. Thomas, F. Froussart, A. Bochot, F. Azan, R. Gurny, D. BenEzra, F. Behar-Cohen, Intraocular implants for extended drug delivery: therapeutic applications, Adv. Drug Deliv. Rev. 58 (2006) 1182-1202.
107. P.A. Flores, D.L. Longworth, The new non-HIV antivirals and antifungals: review and assessment for the formulary, Formulary 32 (1997) 386-406.
108. L.L. Lim, J.R. Smith, J.T. Rosenbaum, Retisert Bausch & Lomb/control delivery systems, Curr. Opin. Investig. Drugs 6 (2005) 1159-1167.
109. S.S. Lee, P. Hughes, A.D. Ross, M.R. Robinson, Biodegradable implants for sustained drug release in the eye, Pharm. Res. 27 (2010) 2043-2053.
110. J.A. Haller, F. Bandello, R. Belfort Jr., M.S. Blumenkranz, M. Gillies, J. Heier, A. Loewenstein, Y.H. Yoon, M.L. Jacques, J. Jiao, X.Y. L.i, S.M. Whitcup, Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion, Ophthalmology 117 (2010) 1134-1146 e3.
111. M.J. Goff, R.N. Johnson, H.R. McDonald, E. Ai, J.M. Jumper, A. Fu, Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration, Retina 27 (2007) 432-438.
112. N. Ferrara, L. Damico, N. Shams, H. Lowman, R. Kim, Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration, Retina 26 (2006) 859-870.
113. E.W.M. Ng, D.T. Shima, P. Calias, E.T. Cunningham Jr., D.R. Guyer, A.P. Adamis, Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease, Nat. Rev. Drug Discov. 5 (2006) 123-132.
114. S. Kundu, P.K. Sahoo, Recent trends in the developments of orally disintegrating tablet technology, Pharma Times 40 (4) (2008) 11-15.
115. F Liu, MM He, JR Nyshadham, K Sharma, JS Chu, P Alto, JA Fix. Water Soluble Polymer-Based Rapidly Dissolving Tablets and Production Process thereof, US patent (2003), 0,129,226 A1
116. Y. Fu, S. Yang, S.H. Jeong, S. Kimura, K. Park, Orally fast disintegrating tablets: developments, technologies, taste-masking and clinical studies, Crit. Rev. Ther. Drug Carrier Syst. 21 (6) (2004) 433-475.
117. F. AlHusban, Y. Perrie, A.R. Mohammed, Formulation of multiparticulate systems as lyophilised orally disintegrating tablets, Eur. J. Pharm. Biopharm. 79 (3) (2011) 627-634.
118. I.J. Cook, P.J. Kahrilas, A.G.A. Technical, Review on management of oropharyngeal dysphagia, Gastroenterology 116 (1999) 455-478.
119. F. AlHusban, A. ElShaer, J. Kansara, A. Smith, L. Grover, Y. Perrie, A.R. Mohammed, Investigation of formulation and process of lyophilised orally disintegrating tablet (ODT) using novel amino acid combination, Pharmaceutics 2 (1) (2010) 1-17.
120. F. AlHusban, Y. Perrie, A.R. Mohammed, Formulation and characterisation of lyophilised rapid disintegrating tablets using amino acids as matrix forming agents, Eur. J. Pharm. Biopharm. 75 (2) (2010) 254-262.
121. Y Fu, C Pai, SY Park, G Seomoon, K Park. Highly Plastic Granules for Making Fast Melting Tablets. US patent (2005), 0,013,857 A1
122. JP Remon, and S Corveleyn, Freeze-Dried Disintegrating Tablets, US patent (2000), 6,010,719.
123. N. Jessop, Impact of ageing, Pharm. Technol. Eur. 23 (12) (2011) 15-16.